RBC Capital analyst Luca Issi downgraded Korro Bio (KRRO) to Sector Perform from Outperform with a price target of $8, down from $85. The company reported “disappointing” first look at human data for KRRO-110, the analyst tells investors in a research note. RBC remains believers in what Korro’s broader platform can do longer term, but downgrades the shares on the failed study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
- Korro Bio downgraded to Market Perform from Strong Buy at Raymond James
- Korro Bio downgraded to Neutral from Buy at Chardan
- Korro Bio Reports Increased Losses Amid Strategic Developments
- Korro Bio downgraded to Hold from Buy at Clear Street